Kathrin U Jansen

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects"
    Kathrin U Jansen
    Pfizer Inc, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 31:2723-30. 2013
  2. ncbi request reprint The path to developing a cervical cancer vaccine
    Kathrin U Jansen
    Vaccine Research and Early Development, Pfizer Inc, USA
    Hum Vaccin 6:777-9. 2010
  3. pmc Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY, USA
    J Infect Dis 205:1688-96. 2012
  4. pmc Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease
    Shannon L Harris
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:68-74. 2011
  5. pmc A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure
    Julio Hawkins
    Pfizer Vaccine Research, Pearl River, New York, USA
    Clin Vaccine Immunol 19:1641-50. 2012
  6. doi request reprint Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
  7. ncbi request reprint Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity
    Ellen Murphy
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:51-9. 2011
  8. pmc Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease
    Lisa K McNeil
    Pfizer Vaccine Research, Pearl River, New York, USA
    Microbiol Mol Biol Rev 77:234-52. 2013
  9. pmc The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
    David Cooper
    Pfizer Vaccine Research, Pfizer, Pearl River, NY 10965, United States
    Vaccine 29:7207-11. 2011
  10. ncbi request reprint 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model
    Philip Fernsten
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:75-84. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects"
    Kathrin U Jansen
    Pfizer Inc, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 31:2723-30. 2013
    ..This review summarizes the potential underlying reasons why these two approaches may have failed, and proposes avenues that may provide successful vaccine approaches to prevent S. aureus disease in the future...
  2. ncbi request reprint The path to developing a cervical cancer vaccine
    Kathrin U Jansen
    Vaccine Research and Early Development, Pfizer Inc, USA
    Hum Vaccin 6:777-9. 2010
    ..Working and interacting with many dedicated and brilliant scientists and taking apprenticeships to become a better and more versatile scientist have been rewarding experiences and more than once luck has come into play...
  3. pmc Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY, USA
    J Infect Dis 205:1688-96. 2012
    ..This is the first description of a protein that has the potential to provide protection across the staphylococcal species group...
  4. pmc Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease
    Shannon L Harris
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:68-74. 2011
    ..These promising findings suggest that a bivalent fHBP vaccine may be capable of providing protection against meningococcal disease caused by both serogroup C and B...
  5. pmc A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure
    Julio Hawkins
    Pfizer Vaccine Research, Pearl River, New York, USA
    Clin Vaccine Immunol 19:1641-50. 2012
    ..These functional antibodies were also able to displace S. aureus already bound to Fg, suggesting that the ligand-binding activity of ClfA can be effectively neutralized through vaccination...
  6. doi request reprint Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  7. ncbi request reprint Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity
    Ellen Murphy
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:51-9. 2011
    ..Our study also revealed evidence for the de-evolution of ClfB and therefore its reduced suitability as a target for vaccine development compared to ClfA...
  8. pmc Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease
    Lisa K McNeil
    Pfizer Vaccine Research, Pearl River, New York, USA
    Microbiol Mol Biol Rev 77:234-52. 2013
    ..This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to N. meningitidis, and its potential role as a vaccine for preventing MnB disease...
  9. pmc The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
    David Cooper
    Pfizer Vaccine Research, Pfizer, Pearl River, NY 10965, United States
    Vaccine 29:7207-11. 2011
    ..Taken together these results suggest that immunization with PCV13 has the potential to induce cross-protective responses to related serotypes not directly covered by the vaccine...
  10. ncbi request reprint 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model
    Philip Fernsten
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:75-84. 2011
    ..These data suggest that PCV13 will provide protection against pneumococcal serotype 1, 3, and 5 disease in human populations, even at relatively low OPA titers...
  11. doi request reprint New frontiers in meningococcal vaccines
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY 10965, USA
    Expert Rev Vaccines 10:617-34. 2011
    ..As these challenges are met, the possibility for removing the fear of meningococcal disease from all societies is now becoming a reality...
  12. doi request reprint Preservative of choice for Prev(e)nar 13™ in a multi-dose formulation
    Lakshmi Khandke
    Pfizer Vaccines Research, Pfizer Biotherapeutics Pharmaceutical Research and Development, 401 North Middletown Road, Pearl River, NY 10965, USA
    Vaccine 29:7144-53. 2011
    ..These results indicate that 2-PE provides a superior antimicrobial effectiveness over Thimerosal for this vaccine formulation...
  13. doi request reprint Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design
    Jasdeep S Nanra
    Wyeth Vaccine Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 27:3276-80. 2009
    ..The data presented in this report support a multiantigen approach for the development of a prophylactic S. aureus vaccine to ensure broad coverage against this versatile pathogen...
  14. doi request reprint Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
    Lisa K McNeil
    Wyeth Research, 401 N Middletown Rd, Pearl River, NY 10965, United States
    Vaccine 27:3417-21. 2009
    ..The data presented in this paper demonstrates that Cap B does not interfere with the binding of antibodies to LP2086 expressed on the outer membrane of MnB clinical isolates...
  15. doi request reprint Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC
    Alexey Gribenko
    Pfizer Vaccine Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    J Mol Biol 425:3429-45. 2013
    ..Therefore, it is unlikely that antibody binding to this antigen will be affected by the occupancy of the metal-binding site by Mn²⁺...